Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-30T00:30:10.237Z Has data issue: false hasContentIssue false

2 - Radiotherapy and chemoradiotherapy of the head and neck

Published online by Cambridge University Press:  24 August 2009

Robert Hermans
Affiliation:
University Hospital Leuven, Belgium
Get access

Summary

Introduction

Radiation oncology plays a major role in the treatment of cancers of the head and neck. It can be used as the only treatment modality or as an adjuvant treatment in combination with surgery. In recent years, it has been frequently used in combination with chemotherapy, mainly to preserve organ function.

In the last decades, important advances in the delivery of radiotherapy have been made, making it possible to deliver high doses of radiation to the tumor, while maximally sparing the surrounding tissues. These developments imply, however, a very accurate delineation of the tumor-involved tissues, which can only be made via the use of imaging techniques.

(Chemo)radiotherapy in head and neck cancer

Selection of a treatment modality

Selection of a treatment modality for head and neck cancer should be based on the size and location of the primary tumor, the status of the regional lymph nodes and the general condition of the patient. Early head and neck cancers are usually treated with one modality – either surgery or radiation therapy. The choice between surgery and radiation therapy in these cases is usually determined by the functional deficit that would result from each treatment modality, since both result in similar rates of local control and survival. Cancers at a locally advanced stage can be treated with a combination of surgery and (chemo)radiotherapy or with primary (chemo)radiotherapy. Chemoradiotherapy can be used when organ preservation is feasible, with surgery as an optional salvage treatment.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Forastiere, A. A., Goepfert, H., Maor, M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349 (2003), 2091–2098.CrossRefGoogle ScholarPubMed
Bourhis, J., Overgaard, J., Audry, H., et al. for the Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet, 368 (2006), 843–584.CrossRefGoogle ScholarPubMed
Budach, W., Hehr, T., Budach, V., Belka, C., Dietz, K.. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 6 (2006), 28.CrossRefGoogle ScholarPubMed
Peters, L. J., Goepfert, H., Ang, K. K., et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys 26 (1993), 3–11.CrossRefGoogle ScholarPubMed
Ang, K. K., Trotti, A., Brown, B. W., et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 51 (2001), 571–578.CrossRefGoogle ScholarPubMed
Bernier, J., Domenge, C., Ozsahin, M., et al. European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 (2004), 1945–1952.CrossRefGoogle ScholarPubMed
Cooper, J. S., Pajak, T. F., Forastiere, A. A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 (2004), 1937–1944.CrossRefGoogle ScholarPubMed
Pignon, J. P., Bourhis, J., Domenge, C., , L.Designe for the MACH-NC Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 355 (2000), 949–955.CrossRefGoogle Scholar
Bourhis, J., Amand, C., , J.P.Pignon for the MACH-NC Collaborative Group. Update of the MACH-NC (meta-analysis of chemotherapy in head and neck cancer) database focused on concomitant chemoradiotherapy. J Clin Oncol 22 (2004), S5505.CrossRefGoogle Scholar
Posner, M. R, Glisson, B., Frenette, G., et al. Multicenter phase I–II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 19 (2001), 1096–1104.CrossRefGoogle ScholarPubMed
Vermorken, J. B., Remenar, E., Herpen, C., et al. Standard cisplatin/infusional 5-fluorouracil (PF) vs. docetaxel (T) plus PF (TPF) as neo-adjuvant chemotherapy for non-resectable locally advanced head and neck cancer (LAHNC): a phase III of the EORTC head and neck cancer group (EORTC 24971). J Clin Oncol 22 (2004), S5508.CrossRefGoogle Scholar
Hitt, R., Grau, J., Lopez-Pousa, A., et al. Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. CRT alone for patients with unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol 24 (2006), S5515.Google Scholar
Bonner, J. A., Harari, P. M., Giralt, J., et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 354 (2006), 567–578.CrossRefGoogle ScholarPubMed
Enami, B., Sethi, A., Petruzelli, G. J.. Influence of MRI on target volume delineation and IMRT planning in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 57 (2003), 481–488.CrossRefGoogle Scholar
Chung, N. N., Ting, L. L., Hsu, W. C., Lui, L. T., Wang, P. M.. Impact of magnetic resonance imaging versus CT on nasopharyngeal carcinoma: primary tumor target delineation for radiotherapy. Head Neck 26 (2004), 241–246.CrossRefGoogle ScholarPubMed
Scarfone, C., Lavely, W. C., Cmelak, A. J., et al. Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging. J Nucl Med 45 (2004), 543–552.Google Scholar
Koshy, M., Paulino, A. C., Howell, R., et al. F-18 FDG PET-CT fusion in radiotherapy treatment planning for head and neck cancer. Head Neck 27 (2005), 494–502.CrossRefGoogle ScholarPubMed
Paulino, A. C., Koshy, M., Howell, R., Schuster, D., Davis, L. W.. Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 61 (2005), 1385–1392.CrossRefGoogle ScholarPubMed
Ciernik, F. I., Dizendorf, E., Baumert, B., et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 57 (2003), 853–863.CrossRefGoogle ScholarPubMed
Nishioka, T., Shiga, T., Shirato, H., et al. Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys 53 (2002), 1051–1057.CrossRefGoogle ScholarPubMed
Rischin, D., Hicks, R. J., Fisher, R., et al. for the Trans-Tasman Radiation Oncology Group Study 98.02. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 24 (2006), 2098–2104.CrossRefGoogle ScholarPubMed
Chao, C., Bosch, W. R., Mutic, S., et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 49 (2001), 1171–1182.CrossRefGoogle ScholarPubMed
Khoo, V. S., Joon, D. L.. New developments in MRI for target volume delineation in radiotherapy. Br J Radiol 79 (2006), S2–S15.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×